T. Rowe Price Associates
ACH

T. Rowe Price Associates’s Accendra Health ACH Stock Holding History

T. Rowe Price Associates’s Portfolio ACH Stock Details ACH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$352K Buy
102,743
+21,025
+26% +$65.4K ﹤0.01% 2782
2026
Q1 		$187K Buy
81,718
+1,810
+2% +$4.17K ﹤0.01% 2866
2025
Q4 		$224K Buy
79,908
+14,079
+21% +$50.3K ﹤0.01% 2773
2025
Q3 		$316K Buy
65,829
+3,017
+5% +$19.2K ﹤0.01% 2580
2025
Q2 		$572K Buy
62,812
+3,123
+5% +$23K ﹤0.01% 2240
2025
Q1 		$539K Buy
59,689
+2,473
+4% +$26.1K ﹤0.01% 2225
2024
Q4 		$748K Buy
57,216
+2,986
+6% +$39.8K ﹤0.01% 2100
2024
Q3 		$851K Buy
54,230
+738
+1% +$11.2K ﹤0.01% 2042
2024
Q2 		$723K Buy
53,492
+5,206
+11% +$107K ﹤0.01% 2033
2024
Q1 		$1.34M Buy
48,286
+2,671
+6% +$59.3K ﹤0.01% 1760
2023
Q4 		$880K Buy
45,615
+1,862
+4% +$33.7K ﹤0.01% 1926
2023
Q3 		$708K Buy
43,753
+3,744
+9% +$66.4K ﹤0.01% 1957
2023
Q2 		$762K Buy
40,009
+1,101
+3% +$19.6K ﹤0.01% 1937
2023
Q1 		$567K Buy
38,908
+872
+2% +$15.6K ﹤0.01% 2056
2022
Q4 		$743K Buy
38,036
+2,747
+8% +$53.6K ﹤0.01% 1937
2022
Q3 		$851K Buy
35,289
+1,515
+4% +$46.7K ﹤0.01% 1838
2022
Q2 		$1.06M Buy
33,774
+767
+2% +$27.8K ﹤0.01% 1869
2022
Q1 		$1.45M Buy
33,007
+677
+2% +$29.1K ﹤0.01% 1821
2021
Q4 		$1.41M Sell
32,330
-4,465
-12% -$175K ﹤0.01% 1856
2021
Q3 		$1.15M Sell
36,795
-3,347
-8% -$132K ﹤0.01% 1985
2021
Q2 		$1.7M Buy
40,142
+5,349
+15% +$208K ﹤0.01% 1809
2021
Q1 		$1.31M Sell
34,793
-108
-0.3% -$3.38K ﹤0.01% 1914
2020
Q4 		$944K Buy
34,901
+10,008
+40% +$257K ﹤0.01% 1971
2020
Q3 		$625K Buy
+24,893
New +$363K ﹤0.01% 2002
2020
Q2 		– Sell
-33,985
Closed -$311K – 2530
2020
Q1 		$311K Buy
33,985
+304
+0.9% +$1.83K ﹤0.01% 2175
2019
Q4 		$174K Buy
33,681
+2,443
+8% +$15.7K ﹤0.01% 2419
2019
Q3 		$181K Buy
31,238
+313
+1% +$1.4K ﹤0.01% 2399
2019
Q2 		$99K Buy
30,925
+100
+0.3% +$341 ﹤0.01% 2479
2019
Q1 		$126K Buy
30,825
+20,000
+185% +$126K ﹤0.01% 2452
2018
Q4 		$69K Sell
10,825
-2,097
-16% -$21.8K ﹤0.01% 2510
2018
Q3 		$213K Buy
+12,922
New +$220K ﹤0.01% 2450
2017
Q4 		– Sell
-21,284
Closed -$621K – 2598
2017
Q3 		$621K Buy
21,284
+8,313
+64% +$245K ﹤0.01% 2002
2017
Q2 		$418K Sell
12,971
-1
-0% -$33 ﹤0.01% 2127
2017
Q1 		$449K Buy
12,972
+1,900
+17% +$67.8K ﹤0.01% 2105
2016
Q4 		$391K Sell
11,072
-14,900
-57% -$503K ﹤0.01% 2155
2016
Q3 		$902K Buy
25,972
+8,677
+50% +$304K ﹤0.01% 1779
2016
Q2 		$646K Buy
17,295
+535
+3% +$20.1K ﹤0.01% 1858
2016
Q1 		$677K Hold
16,760
– – ﹤0.01% 1853
2015
Q4 		$603K Buy
16,760
+2,260
+16% +$81.8K ﹤0.01% 1880
2015
Q3 		$463K Hold
14,500
– – ﹤0.01% 1987
2015
Q2 		$493K Hold
14,500
– – ﹤0.01% 2011
2015
Q1 		$491K Buy
14,500
+2,200
+18% +$76.6K ﹤0.01% 1980
2014
Q4 		$432K Hold
12,300
– – ﹤0.01% 2018
2014
Q3 		$403K Hold
12,300
– – ﹤0.01% 2032
2014
Q2 		$418K Hold
12,300
– – ﹤0.01% 2026
2014
Q1 		$431K Buy
12,300
+2,200
+22% +$77.6K ﹤0.01% 1981
2013
Q4 		$369K Hold
10,100
– – ﹤0.01% 2040
2013
Q3 		$349K Buy
10,100
+2,300
+29% +$80.5K ﹤0.01% 2046
2013
Q2 		$264K Buy
+7,800
New +$259K ﹤0.01% 2123

Other funds holding ACH

CCM
Coliseum Capital Management Rowayton, Connecticut $1.16B AUM 23.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
ICM
Invenomic Capital Management Boston, Massachusetts $1.67B AUM 1.43% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
PCMI
Paradigm Capital Management Inc Albany, New York $3.67B AUM 121.12% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

T. Rowe Price Associates's ACH Position: Q2 2026 in Review

T. Rowe Price Associates increased its Accendra Health (ACH) stake by 26% in Q2 2026, buying an estimated $65.4K and bringing the position to 102,743 shares worth $352K. The position accounts for ﹤0.01% of the portfolio, ranked #2782.

T. Rowe Price Associates first reported a position in ACH in Q2 2013 and has held it in 49 quarters since. The position peaked at $1.7M in Q2 2021. 139 funds tracked by Wall St. Rank hold ACH as of Q2 2026.

  • T. Rowe Price Associates held 102,743 shares of Accendra Health worth $352K as of Q2 2026.
  • T. Rowe Price Associates bought 21,025 Accendra Health shares in Q2 2026, an estimated $65.4K.
  • Accendra Health made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #2782 holding.
  • T. Rowe Price Associates first reported a position in Accendra Health in Q2 2013 and has held it in 49 quarters since.
  • T. Rowe Price Associates's Accendra Health position peaked at $1.7M in Q2 2021.
  • 139 funds tracked by Wall St. Rank held Accendra Health as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.